Pharmacological reports : PR 2012-01-01

Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.

Zofia Rogóż

Index: Pharmacol. Rep. 64(6) , 1567-72, (2012)

Full Text: HTML

Abstract

Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia.The present study was aimed at examining the effect of mirtazapine and risperidone, given separately or jointly in mice, on the locomotor hyperactivity induced by D-amphetamine or MK-801 as well as a 5-HT(2A) receptor agonist DOI-induced head twitches as models for positive symptoms of psychosis.The obtained results showed that co-treatment with mirtazapine (2.5 or 5 mg/kg) and risperidone (0.01 mg/kg) inhibited the locomotor hyperactivity induced by D-amphetamine or MK-801. Moreover, co-administration of mirtazapine (1.25 or 2.5 mg/kg) and risperidone (0.01 mg/kg) reduced the number of head twitches induced by DOI, whereas those drugs given separately changed neither the locomotor hyperactivity induced by D-amphetamine or MK-801 nor the syndrome induced by DOI.The obtained results indicated that lower doses of mirtazapine enhanced the antipsychotic-like effect of risperidone in animal tests of positive symptoms of schizophrenia. Further studies are necessary to elucidate its mechanism of action.


Related Compounds

Related Articles:

Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.

2014-12-01

[Neurobiol. Learn. Mem. 116 , 162-71, (2014)]

Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.

2014-09-01

[J. Pharmacol. Exp. Ther. 350(3) , 589-604, (2014)]

Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.

2014-01-01

[Drug Metab. Pharmacokinet. 29(5) , 419-26, (2014)]

A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.

2015-01-01

[J. Thromb. Thrombolysis 39(1) , 79-88, (2015)]

Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples

2014-11-01

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 970 , 1-7, (2014)]

More Articles...